France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline

None Ipsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in cash for an initial estimated aggregate consideration of $952 million plus one contingent value right (CVR) per share. • None Each CVR will entitle its holder to deferred cash payments of $10.00…#biliary #fda #albireopharmainc #bylvay #ipsen #nonepriceaction #albireo
Source: Reuters: Health - Category: Consumer Health News Source Type: news